Double umbilical cord blood transplantation for hematological malignancies: a long- term analysis from the SFGM-TC registry. - Centre de recherche en cancérologie Nantes-Angers Unité Mixte de Recherche 892 Inserm - 6299 CNRS Accéder directement au contenu
Article Dans Une Revue Experimental Hematology Année : 2013

Double umbilical cord blood transplantation for hematological malignancies: a long- term analysis from the SFGM-TC registry.

Hélène Labussière Wallet
  • Fonction : Auteur
Mohamad Sobh
  • Fonction : Auteur
Sabine Fürst
  • Fonction : Auteur
Eric Deconinck
Anne Sirvent
  • Fonction : Auteur
Marc Renaud
Nathalie Dhedin
  • Fonction : Auteur
Sébastien Maury
  • Fonction : Auteur
Agnès Buzyn
  • Fonction : Auteur
Gérard Michel
  • Fonction : Auteur
Jean-Yves Cahn
  • Fonction : Auteur
Ibrahim Yacoub-Agha
  • Fonction : Auteur
Evelyne Marry
  • Fonction : Auteur
Marie-Lorraine Balère
  • Fonction : Auteur
Vanderson Rocha
  • Fonction : Auteur
Gérard Socié
Didier Blaise
Noël Milpied
  • Fonction : Auteur

Résumé

: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for many hematological malignancies for which umbilical cord blood (UCB) represents an alternative source of HSC. In order to overcome the low cellularity of one UCB unit, double UCBT (dUCBT) has been developed in adults. We have analyzed the outcome of 136 patients who underwent dUCBT reported to the SFGM-TC registry between 2005 and 2007. Forty-six patients received myeloablative and 90 reduced intensity conditioning regimens. There were 84 leukemias, 17 NHL, 11 myelomas and 24 other hematological malignancies. At transplantation, 40 (29%) patients were in CR1. At day 60 after transplantation, the cumulative incidence of neutrophil recovery was 91%. We observed one UCB unit domination in 88% of cases. The cumulative incidence of day 100 aGVHD, cGVHD, TRM and relapse at 2 years were 36%, 23%, 27% and 28% respectively. After a median follow-up of 49.5 months, the 3 years probabilities of overall and progression-free survival were 41% and 35% respectively with a significant OS advantage when male cord engrafted male recipients. We obtained a long term plateau among patients in CR1 which makes dUCBT a promising treatment strategy for these patients.

Domaines

Cancer

Dates et versions

hal-00849674 , version 1 (31-07-2013)

Identifiants

Citer

Hélène Labussière Wallet, Mohamad Sobh, Stéphane Morisset, Marie Robin, Nathalie Fegueux, et al.. Double umbilical cord blood transplantation for hematological malignancies: a long- term analysis from the SFGM-TC registry.. Experimental Hematology, 2013, 41 (11), pp.924-933. ⟨10.1016/j.exphem.2013.05.297⟩. ⟨hal-00849674⟩
1886 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More